AU2002347984A1 - Use of norepinephrine reuptake inhibitors for the treatment of tic disorders - Google Patents

Use of norepinephrine reuptake inhibitors for the treatment of tic disorders

Info

Publication number
AU2002347984A1
AU2002347984A1 AU2002347984A AU2002347984A AU2002347984A1 AU 2002347984 A1 AU2002347984 A1 AU 2002347984A1 AU 2002347984 A AU2002347984 A AU 2002347984A AU 2002347984 A AU2002347984 A AU 2002347984A AU 2002347984 A1 AU2002347984 A1 AU 2002347984A1
Authority
AU
Australia
Prior art keywords
treatment
reuptake inhibitors
norepinephrine reuptake
tic disorders
tic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002347984A
Other languages
English (en)
Inventor
Albert John Allen
David Michelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002347984A1 publication Critical patent/AU2002347984A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002347984A 2001-11-30 2002-11-12 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders Abandoned AU2002347984A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33449401P 2001-11-30 2001-11-30
US60/334,494 2001-11-30
PCT/US2002/033628 WO2003047560A1 (en) 2001-11-30 2002-11-12 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders

Publications (1)

Publication Number Publication Date
AU2002347984A1 true AU2002347984A1 (en) 2003-06-17

Family

ID=23307469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002347984A Abandoned AU2002347984A1 (en) 2001-11-30 2002-11-12 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders

Country Status (12)

Country Link
US (2) US20050014843A1 (enExample)
EP (1) EP1455770B1 (enExample)
JP (1) JP2005515199A (enExample)
KR (1) KR20050044604A (enExample)
AT (1) ATE365035T1 (enExample)
AU (1) AU2002347984A1 (enExample)
CA (1) CA2466649A1 (enExample)
DE (1) DE60220825T2 (enExample)
DK (1) DK1455770T3 (enExample)
ES (1) ES2287338T3 (enExample)
PT (1) PT1455770E (enExample)
WO (1) WO2003047560A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005522445A (ja) * 2002-02-12 2005-07-28 サイプレス バイオサイエンス， インコーポレイテッド 注意欠陥過活動性障害（ａｄ／ｈｄ）の処置方法
WO2005060949A2 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
WO2006077846A1 (ja) * 2005-01-18 2006-07-27 Mitsubishi Pharma Corporation 注意欠陥/多動性障害治療薬
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
KR102096165B1 (ko) 2018-05-03 2020-04-01 노충구 틱 장애 개선 및 치료 효과를 가지는 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
ES2258010T3 (es) * 1999-07-01 2006-08-16 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar el dolor cronico.
PT1257277E (pt) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション

Also Published As

Publication number Publication date
PT1455770E (pt) 2007-09-06
EP1455770B1 (en) 2007-06-20
DE60220825D1 (de) 2007-08-02
WO2003047560A1 (en) 2003-06-12
DE60220825T2 (de) 2008-03-06
CA2466649A1 (en) 2003-06-12
DK1455770T3 (da) 2007-10-08
US20080200555A1 (en) 2008-08-21
EP1455770A1 (en) 2004-09-15
ATE365035T1 (de) 2007-07-15
ES2287338T3 (es) 2007-12-16
KR20050044604A (ko) 2005-05-12
US20050014843A1 (en) 2005-01-20
JP2005515199A (ja) 2005-05-26

Similar Documents

Publication Publication Date Title
MY169308A (en) Treatment of tnf? related disorders
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
MY140767A (en) Compounds, methods and compositions
MY134110A (en) Combinations of reboxetine and neuroleptic agents
IL182417A0 (en) Mitotic kinesin inhibitors and methods of use thereof
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
MY136367A (en) Treatment of cognitive failure
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
WO2001066101A3 (en) Treatment of psoriasis
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
AU4910500A (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase